Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
About this trial
This is an interventional treatment trial for Esophageal Squamous Cell Carcinoma focused on measuring esophageal squamous cell carcinoma, immunotherapy, chemotherapy, surgery, adjuvant therapy
Eligibility Criteria
Inclusion Criteria: Aged between 18 and 70 years Untreated before surgery (e.g. radiotherapy, chemotherapy, target therapy and immunotherapy) Histologically documented squamous cell carcinoma of the thoracic esophagus with positive lymph nodes (T1-3N1-3M0) undergoing radical esophagectomy ECOG (Eastern Cooperative Oncology Group) : 0-1 No recurrent disease before adjuvant therapy Normal hemodynamic indices before the recruitment Able to understand this study and have signed informed consent Exclusion Criteria: previous or concurrent malignancy Interstitial lung disease Requiring systemic treatment with either corticosteroids or other immunosuppressive medications Known or suspected allergy to chemotherapeutic drugs or Tislelizumab Active autoimmune disease Active hepatitis Those whom the investigator considered unsuitable for inclusion
Sites / Locations
- Cancer Hospital of Shantou University Medical CollegeRecruiting
Arms of the Study
Arm 1
Experimental
Adjuvant Chemotherapy in Combination With Immunotherapy
Adjuvant Chemotherapy in Combination With Tislelizumab was used in patients with Lymph Node-Positive Esophageal Squamous Cell Carcinoma after surgery